A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of BHV-3500 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2018
At a glance
- Drugs BHV-3500 (Primary)
- Indications Migraine
- Focus Adverse reactions
- 12 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the trial is scheduled to begin in the first half of 2018.
- 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company Ltd media release, the company remains on track to submit an investigational new drug application (IND) in first half of 2018 for BHV-3500 for the acute treatment and prevention of migraine and expects to conduct this trial in the second half of 2018.
- 26 Feb 2018 New trial record